Login to Your Account



Taigen aims to enhance AML therapy with only in-house asset, burixafor

By Cornelia Zou
Staff Writer

Monday, May 4, 2015
HONG KONG – Taigen Biotechnology Co. Ltd. started the first clinical trials of its stem cell mobilizer drug, burixafor (TG-0054), in mainland China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription